To add to your comments, this failure makes Noxopharm even more valuable if we can only replicate DARRT 1 trial results, with 4 abscopal responses, lower PSA and better quality of life for patients by reducing pain and suffering.
The initial IONIC trial was only meant to have 2-3 trial sites now there are 6 participating now, and the fact that BMS is paying for everything i would say that they may be seeing some positive results otherwise why continue, 12 months in and adding 22 new patients with a total of 33 participating looks very promising.
IONIC may yet be a winner, page-3
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.010(9.52%) |
Mkt cap ! $33.60M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 14.0¢ | 11.0¢ | $559.0K | 4.481M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6612 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 99714 | 1 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |